[18F]MK-3328 as a Possible Novel Positron Emission Tomography (PET) Tracer for the Detection of Brain Amyloid Plaques (MK-3328-002)

NCT01385033 | Terminated Phase 1 Results

• 1 other identifier: 3328-002
• Study Type: interventional
• Target: 20
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this study is to evaluate radiolabeled \[18F\]MK-3328 as a PET tracer for estimating the regional distribution and extent of amyloid plaques in participants suffering from amnestic mild cognitive impairment (aMCI) and Alzheimer's Disease (AD) versus healthy young and elderly participants. The study hypotheses will test whether \[18F\]MK-3328 can discriminate between AD participants and cognitively normal elderly control participants as measured by brain regional tracer uptake.

Conditions

Alzheimer's Disease

Outcome Measures

Primary Outcomes (3)

• Area Under the Receiver Operating Curve (AUC of ROC) for Distinguishing Between AD and HE Participants Based on Brain Cortical [18F]MK-3328 Standard Uptake Value Ratio (SUVR)

  Using PET brain images acquired after dosing, regions of interest (ROIs) are drawn in identified brain areas. The ROIs are projected onto all frames of the dynamic PET scans in order to generate \[18F\]MK-3328 tissue time-activity curves (TACs). SUVR is calculated as the ratio of the average \[18F\]MK-3328 uptake over 60-90 minutes post dose in the target brain region and the cerebellum. Cortical SUVR is determined, which is a mean SUVR derived from SUVR from multiple brain regions (frontal cortex, parietal cortex, anterior cingulate gyrus, posterior cingulate gyrus, temporal cortex, lateral temporal cortex and occipital cortices). The receiver operating curve (ROC) for determining whether a participant is in HE or AD group by using cortical SUVR values is determined. The ROC is a plot of sensitivity on the y-axis versus 1-specificity (false positive rate) on the x-axis for the range of cortical SUVR threshold values. The AUC of ROC is determined.

  60-90 minutes post dose

• Brain Cortical [18F]MK-3328 SUVR in AD Participants and HE Participants

  Using PET brain images acquired after dosing, ROIs are drawn in identified brain areas. The ROIs are projected onto all frames of the dynamic PET scans in order to generate \[18F\]MK-3328 tissue TACs. SUVR is calculated as the ratio of the average \[18F\]MK-3328 uptake over 60-90 minutes post dose in the target brain region and the cerebellum. Cortical SUVR is reported, which is a mean SUVR derived from SUVR from multiple brain regions (frontal cortex, parietal cortex, anterior cingulated gyrus, posterior cingulated gyrus, temporal cortex, lateral temporal cortex and occipital cortices). A trimming procedure will be applied to remove the sub-population of HE participants who have positive amyloid plaque burden. The 1st and 2nd quartiles of the cortical SUVR distribution, Q1 and Q2, are computed for HE data; values with SUVR ≥(Q2-Q1)\*3 are removed before calculation of HE mean (trimmed) and standard deviation (SD)(trimmed).

  60-90 minutes post dose

• Amyloid Plaque Burden Threshold Determined by the Trimmed HE Sample Mean and SD Brain Cortical [18F]MK-3328 SUVR

  Using PET brain images acquired after dosing, ROIs are drawn in identified brain areas. ROIs are projected onto all frames of the dynamic PET scans in order to generate \[18F\]MK-3328 tissue TACs. SUVR is calculated as the ratio of the average \[18F\]MK-3328 uptake over 60-90 minutes post dose in the target brain region and the cerebellum. Cortical SUVR is determined, which is a mean SUVR derived from SUVR from multiple brain regions. The 1st and 2nd quartiles of the cortical SUVR distribution, Q1 and Q2, are computed for HE data; values with SUVR ≥(Q2-Q1)\*3 are removed before calculation of HE mean (trimmed) and SD (trimmed). This step is performed to remove HE participants with positive plaque burden. Using HE data, the threshold for classification of plaque burden as positive/negative will be calculated as mean (trimmed) + k\*SD (trimmed). Value of k will be chosen to fine tune sensitivity/specificity, with specificity of at least 0.9 in the sub-group remaining after trimming of data.

  60-90 minutes post dose

Study Arms (3)

Part I, Healthy Elderly (HE) and AD Participants

EXPERIMENTAL

HE and AD participants will receive a single intravenous (IV) dose of \~150 megabecquerel (MBq) \[18F\]MK-3328 in Part I of the study

Drug: [18F]MK-3328

Part II, Healthy Young, HE and AD Participants

EXPERIMENTAL

Healthy Young, HE and AD participants will receive a single IV dose of \~150 megabecquerel (MBq) \[18F\]MK-3328 in Part II of the study

Drug: [18F]MK-3328

Part III, Participants with aMCI

EXPERIMENTAL

Participants with aMCI will receive a single IV dose of \~150 megabecquerel (MBq) \[18F\]MK-3328 in Part III of the study

Drug: [18F]MK-3328

Interventions

[18F]MK-3328 DRUG

IV dose of \~150 megabecquerel (MBq) \[18F\]MK-3328

Part I, Healthy Elderly (HE) and AD Participants; Part II, Healthy Young, HE and AD Participants; Part III, Participants with aMCI

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• All participants:
• Body Mass Index (BMI) between 18 and 35, inclusive, at the pre-screening visit
• Electrocardiogram (ECG) measurements must be clinically acceptable
• Must consent to apolipoprotein E4 (ApoE4) genotyping
• Healthy young (HY) and healthy elderly (HE) participants:
• Male or female between the ages of 18 and 45 years (HY) and 65 to 85 years (HE) at pre-screening visit
• Judged to be in good health
• Considered generally cognitively normal
• Participants with aMCI or AD:
• Male or female between the ages of 50 and 85 years (aMCI) and 65 to 85 years (AD) at pre-screening visit
• Is in stable medical condition, with existing medical conditions stable for 3 months prior to the pre-screening visit
• Free of any clinically significant disease that would interfere with the study and radiographic evaluations
• Specific cognitive testing requirements for participants aMCI: a history of subjective memory decline with gradual onset and slow progression ≥1 year before Screening, corroborated by an informant; objective impairment in verbal memory as defined by \>1 SD below the age adjusted mean for items remembered on the Delayed Word Recall Task of the Alzheimer's Disease Assessment Scale (ADAS) Cog12 at Screening; a global Clinical Dementia Rating (CDR) score of 0.5 and a memory box score of 0.5 or greater at Screening; and an Mini Mental Status Examination (MMSE) score ≥ 24 at Pre-Screening
• Specific cognitive testing requirements for participants with mild-to-moderate AD: MMSE score between 16 and 23, inclusive, at Pre-Screening; modified Hachinski score ≤4 at Screening; meets National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria for probable AD at Screening; Clinical Dementia Rating (CDR) Scale = 0.5, 1 or 2 at Screening; screening magnetic resonance imaging (MRI) scan consistent with a diagnosis of AD
• Participants with AD must have reliable informant/caregiver who is able to accompany the participant to all clinic visits, is able to provide information to study investigator/staff via telephone contact, and agrees to return for per-protocol follow-up visits and procedures

You may not qualify if:

• Mentally or legally incapacitated, significant emotional problems at the time of pre-screening visit or expected during the conduct of the study, or has a history of a clinically significant psychiatric disorder over the last 2 years
• Medical history of psychiatric or personality disorders that in the opinion of the investigator and sponsor, affects the ability to participate in the trial
• Has received anti-amyloid agents (e.g., tarenflurbil, tramiprosate) in the 3 months period before screening and has received anti-amyloid antibodies (e.g., bapineuzumab) or anti-amyloid vaccine
• Has participated in MK-3328 PN001 trial
• Has a history of any illness that, in the opinion of the study investigator, might confound the results of the study or poses an additional risk by their participation in the study
• Has had any surgical or medical condition that might significantly alter the distribution, metabolism, or excretion of \[18F\]-PET tracer
• Has incidental findings on an MRI scan that is pathognomonic for an active disease or pathological process that requires medical intervention
• Has a history of significant infection within 4 weeks prior to study drug administration that in the opinion of the investigator, affects the ability to participate in the trial
• Has an estimated creatinine clearance of ≤30 mL/min based on the Cockcroft-Gault equation
• Has a history of stroke, chronic seizures, or major neurological disorder
• Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or other diseases that in the opinion of the investigator would prevent them from safely participating in the study
• Has a history of neoplastic disease, except: adequately treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix; other malignancies that have been successfully treated prior to the Pre-Screening visit and appropriate follow-up has revealed no evidence of recurrence; or are highly unlikely to sustain a recurrence for the duration of the study
• Is pregnant, intending to become pregnant within 3 months of ending the study, or is nursing
• Consumes excessive amounts of alcohol, or coffee, tea, cola, or other caffeinated beverages
• Has had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the pre-screening visit

Sponsors & Collaborators

• Merck Sharp & Dohme LLC: lead

MeSH Terms

Conditions

Alzheimer Disease

Condition Hierarchy (Ancestors)

Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders

Results Point of Contact

• Title: Senior Vice President, Global Clinical Development
• Organization: Merck Sharp & Dohme Corp

ClinicalTrialsDisclosure@merck.com

1-800-672-6372

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 8, 2011
• First Posted: June 29, 2011
• Study Start: August 19, 2011
• Primary Completion: May 15, 2012
• Study Completion: May 15, 2012
• Last Updated: November 8, 2018
• Results First Posted: February 20, 2014

Record last verified: 2018-10

Data Sharing

• IPD Sharing: Will share